Cargando…
Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
BACKGROUND: There remain questions around the optimal use of bone-modifying agents (BMAs) in patients with bone metastases from breast and castration-resistant prostate cancer (CRPC). A physician survey was performed to identify current practices, as well as perceptions around long-term BMA use, BMA...
Autores principales: | AlZahrani, Mashari, Clemons, Mark, Vandermeer, Lisa, Sienkiewicz, Marta, Awan, Arif Ali, Hutton, Brian, Pond, Gregory R., Ng, Terry L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689398/ https://www.ncbi.nlm.nih.gov/pubmed/33294318 http://dx.doi.org/10.1016/j.jbo.2020.100339 |
Ejemplares similares
-
Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey
por: Alzahrani, Mashari, et al.
Publicado: (2021) -
Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation
por: McGee, Sharon, et al.
Publicado: (2021) -
Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey
por: McGee, Sharon, et al.
Publicado: (2021) -
Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases
por: Addison, Christina L, et al.
Publicado: (2014) -
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)